Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996985 | 0.80 | OPRM1 (0.65) | OPRM1OPRK1OPRL1 | |
| SCHEMBL2991534 | 0.80 | OPRM1 (0.65) | OPRM1OPRK1OPRL1 | |
| SCHEMBL2996661 | 0.78 | TNKS (0.47) | OPRM1OPRL1CHRM2CHRM4CHRM1 | |
| SCHEMBL27750678 | 0.77 | OPRM1 (0.51) | OPRM1OPRK1OPRL1HTR2AHTR7 | |
| SCHEMBL2988260 | 0.77 | KCNH2 (0.69) | OPRM1OPRK1OPRL1CHRM4CHRM1 | |
| SCHEMBL13243464 | 0.77 | KCNH2 (0.69) | OPRM1OPRK1OPRL1CHRM4CHRM1 | |
| SCHEMBL13243461 | 0.77 | KCNH2 (0.69) | OPRM1OPRK1OPRL1CHRM4CHRM1 | |
| SCHEMBL2995221 | 0.77 | CHRM1 (0.55) | CHRM2CHRM4CHRM1HTR7CHRM3 | |
| SCHEMBL13243467 | 0.77 | OPRM1 (0.60) | OPRM1OPRK1OPRL1CHRM4CHRM1 | |
| SCHEMBL13243419 | 0.74 | OPRM1 (0.57) | OPRM1OPRK1OPRL1CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | claimed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| EP-2035412-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007142585-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007142585-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | CHRM1, CHRM2, CHRM5 | OPRM1 25/4885OPRK1 32/4885OPRL1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.